HER2 Antibody Clone: GR011 Concentrate
- Known as:
- HER2 Antibody Clone: GR011 Concentrate
- Catalog number:
- 61-0154-2
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Genemed
- Gene target:
- HER2 Antibody Clone: GR011 Concentrate
Related genes to: HER2 Antibody Clone: GR011 Concentrate
- Gene:
- ERBB2 NIH gene
- Name:
- erb-b2 receptor tyrosine kinase 2
- Previous symbol:
- NGL
- Synonyms:
- NEU, HER-2, CD340, HER2
- Chromosome:
- 17q12
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2019-04-23
Related products to: HER2 Antibody Clone: GR011 Concentrate
Related articles to: HER2 Antibody Clone: GR011 Concentrate
- Ovarian metastases from colorectal cancer (CRC) are uncommon but are associated with poor prognosis and therapeutic challenges. These lesions may exhibit discordant responses to systemic therapy, suggesting site-specific biological heterogeneity. However, the molecular characteristics of CRC-associated ovarian metastases remain insufficiently defined. We aimed to characterize the circulating tumor deoxyribonucleic acid (ctDNA) landscape of ovarian metastatic CRC using a plasma-based deep sequencing approach. - Source: PubMed
Publication date: 2026/05/22
Iwahashi NaoyukiNoguchi TomokoSakai KazukoYahata TamakiNakata KumikoNishioka KahoFujino MegumiTakeda ShinichiroSuzuki NobuhikoNishio KazutoIno Kazuhiko - Polycystic ovary syndrome (PCOS) is a hormonal disorder marked by irregular menstrual cycles, elevated androgen levels, ovarian cysts, hirsutism, acne and other symptoms. While conventional medications such as Metformin and Spironolactone are commonly prescribed, they are often associated with undesirable side effects. As a result, there is growing interest in alternative treatments, particularly those involving medicinal plants. Vitex negundo L., a member of the Lamiaceae family, has demonstrated promising therapeutic effects against PCOS. However, its precise molecular mechanism of action remains unclear. To explore this, we conducted an untargeted metabolomics analysis using UPLC-MS/MS to identify bioactive compounds, followed by network pharmacology to elucidate potential mechanisms. Metabolite fingerprinting revealed 186 metabolites, among which 122 were identified as secondary metabolites. Network pharmacology analysis uncovered 910 potential targets associated with the identified compounds and 297 known PCOS-related disease targets, with 50 overlapping targets between the two datasets. Key hub targets identified included P53, ESR1, AKT1, STAT3, CTNNB1, ERBB2, BCL2, EGFR, MTOR and IL6. Furthermore, molecular docking highlighted several bioactive constituents-syringin, 4-(3,4-dihydroxyphenyl)-6,7-dihydroxynaphthalene-2-carboxylic acid, and Isovitexin-as potential lead compounds for PCOS treatment. Further evaluation of lead compounds can be conducted through in vitro and in vivo studies. - Source: PubMed
Poojary Nishmitha RVenkatasai Neeharika NarisepalliSanjay Kannath UKodanch Supraja MRai Padmalatha S - Targeted protein degradation mediated by antibodies has emerged as a promising strategy for degrading extracellular or membrane-bound proteins. Proteolysis-Targeting Antibodies (PROTABs) are bispecific antibodies specifically designed to induce the degradation of membrane proteins by tethering them to a cell surface E3 ligase, which promotes ubiquitination and subsequent degradation. Recent studies have demonstrated the potential of PROTABs to degrade oncogenic receptors, but their underlying mechanisms remain to be fully elucidated. Here, we investigated the mechanism of action of a HER2-targeting PROTAB comprising an anti-Zinc and RING finger protein 3 (ZNRF3) arm and an anti-receptor tyrosine-protein kinase erbB-2 (HER2) arm. We show that PROTAB induces rapid ternary complex formation, followed by receptor internalization and degradation, resulting in ~ 85% target depletion within 24 h. Mechanistically, ubiquitination enhances but is not strictly required for internalization, and degradation proceeds predominantly through the lysosomal pathway. Notably, ZNRF3 is not codegraded but instead accumulates at the cell surface, while the PROTAB antibody itself is largely recycled. Importantly, target degradation does not consistently translate into growth inhibition, highlighting the role of cellular context and target dependency. Together, these findings provide a mechanistic framework for PROTAB function and inform the rational design of next-generation antibody-based degraders. - Source: PubMed
Publication date: 2026/08/10
He JieyanSun TaoZhang MengwenSanoyca AliciaTsai Wen-Ting KKee Yee-SeirAgard Nicholas JLi Jing - Glucuronide prodrug strategies may enhance target specificity and reduce the toxicity of PARP inhibitors, but no clinical evaluation has been performed. We evaluated TSL-1502, a novel glucuronide prodrug of a PARP inhibitor, in a randomized, open-label, phase 2 study at 28 sites in China (NCT05420779). Eligible patients were women aged 18-75 years with HER2-negative locally advanced or metastatic breast cancer and germline BRCA mutations. Patients were assigned randomly (2:2:1) to receive TSL-1502 at 350 mg or 500 mg once daily or the investigator's choice of chemotherapy (eribulin, capecitabine, or vinorelbine) in 3-week cycles. Sixty-three patients were enrolled between August 18, 2022, and March 5, 2024. According to the Independent Review Committee assessment, the objective response rates were 36.0% (95% CI, 18.0-57.5) in the 350 mg group, 55.6% (95% CI, 35.3-74.5) in the 500 mg group, and 40.0% (95% CI, 12.2-73.8) in the chemotherapy group. The median progression-free survival times were 5.6 (95% CI, 4.0-8.2), 8.8 (95% CI, 5.7-not assessable [NA]), and 9.2 (95% CI, 1.38-NA) months, respectively, and the overall survival times were 17.4 months (95% CI, 9.1-NA), not reached (95% CI, 16.9-NA), and 19.8 months (95% CI, 9.2-NA), respectively. Grade ≥3 treatment-related adverse events occurred in 60.0%, 59.3%, and 80.0% of patients, with anemia most common in the TSL-1502 group and neutropenia most common with chemotherapy. No treatment-related deaths occurred. TSL-1502 at 500 mg showed promising antitumor activity and a manageable safety profile, supporting further clinical development. - Source: PubMed
Publication date: 2026/08/10
Lan BoXu FaliangSun TaoQiu FumingWang YongshengWang ShoumanLi WeiZhong YahuaWu XinhongOuyang QuchangWang KeMi XiaolanLiu RuiXu Binghe - A 50-year-old female patient noticed a mass and pain in her left breast, and needle biopsy revealed mucinous carcinoma that was negative for hormone receptors and positive for HER2/neu. After further examination, she was diagnosed with left breast cancer, cT3N2aM1 (bone), cStage Ⅳ, and was scheduled to start trastuzumab + pertuzumab + docetaxel (HPD) and denosumab. However, she was urgently admitted to the hospital due to pain caused by bone metastasis, and radiation therapy was performed. After discharge from the hospital, she was started on HPD and zoledronic acid treatment. After 6 doses of HPD, because of Grade 2 lower leg edema, treatment was continued with trastuzumab + pertuzumab (HP) and zoledronic acid only. Eighteen months after the first presentation, she complained of nausea and headache and was diagnosed with breast cancer brain metastasis. Therefore, whole brain irradiation was performed. HP was continued after radiation therapy, but headaches reappeared 33 months after the first presentation, accompanied by recurrence of brain metastasis. Trastuzumab deruxtecan was initiated, and the lesions had almost disappeared on the MRI scan 3 months later. The treatment is ongoing without any major adverse events. - Source: PubMed
Ozaki SaraIwamoto NaokoMiyake MihoHashimoto RikakoMasuda HirokoNakatsugawa NorikoKuwayama Takashi